THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2014

View the entire original 990 at ProPublica ↗

Organization
THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period
2014-10-01 to 2015-09-30
Filed
2016-06-03
IRS object ID
201641559349300129
Schema version
2014v6.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2016-06-03T12:57:48-05:00ReturnTs
Tax Period End2015-09-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1GRANT THORNTON LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1757 THIRD AVE 4TH FLOORAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP100172013ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2014-10-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN133163817EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE FOUNDATION FOR AIDS RESEARCHBusinessNameLine1Txt
FieldValueIRS element (for citing)
In Care Of% BRADLEY JENSENInCareOfNm
Business Name ControlFOUNBusinessNameControlTxt
Phone2128061600PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1120 wall street 13TH FLOORAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP100053908ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonBrad JensenPersonNm
Person TitleCFOPersonTitleTxt
Phone2125990100PhoneNum
Signature2016-06-02SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonScott ThompsettPreparerPersonNm
PTINP00741490PTIN
Phone2125990100PhoneNum
FieldValueIRS element (for citing)
Tax2014TaxYr
Build TS2016-08-17 19:52:53ZBuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

FieldValueIRS element (for citing)
Business Name Line1Aids Research Foundation or AMFARBusinessNameLine1Txt
FieldValueIRS element (for citing)
Principal OfficerKEVIN FROSTPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1120 WALL STREET 13TH FLOORAddressLine1Txt
Citynew yorkCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10005ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$72,911,885GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.AMFAR.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1983FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or Missionamfar is dedicated to ending the global AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH.ActivityOrMissionDesc
Voting Members Governing Body19VotingMembersGoverningBodyCnt
Voting Members Independent19VotingMembersIndependentCnt
Total Employee88TotalEmployeeCnt
Total Volunteers57TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$57,556,516PYContributionsGrantsAmt
CY Contributions Grants$56,251,128CYContributionsGrantsAmt
PY Program Service Revenue$0PYProgramServiceRevenueAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$1,225,465PYInvestmentIncomeAmt
CY Investment Income$1,528,180CYInvestmentIncomeAmt
PY Other Revenue-$10,881,866PYOtherRevenueAmt
CY Other Revenue-$10,047,530CYOtherRevenueAmt
PY Total Revenue$47,900,115PYTotalRevenueAmt
CY Total Revenue$47,731,778CYTotalRevenueAmt
PY Grants And Similar Paid$9,928,384PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$9,528,182CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$9,582,859PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$10,307,568CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$569,004PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$739,793CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$5,533,456CYTotalFundraisingExpenseAmt
PY Other Expenses$14,312,877PYOtherExpensesAmt
CY Other Expenses$17,000,831CYOtherExpensesAmt
PY Total Expenses$34,393,124PYTotalExpensesAmt
CY Total Expenses$37,576,374CYTotalExpensesAmt
PY Revenues Less Expenses$13,506,991PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$10,155,404CYRevenuesLessExpensesAmt
Total Assets BOY$57,895,971TotalAssetsBOYAmt
Total Assets EOY$71,251,093TotalAssetsEOYAmt
Total Liabilities BOY$13,585,624TotalLiabilitiesBOYAmt
Total Liabilities EOY$18,212,471TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$44,310,347NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$53,038,622NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCMissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$15,140,613ExpenseAmt
Grant$5,330,808GrantAmt
Revenue$0RevenueAmt
DescRESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the U.S. National Institutes of Health. FOR FURTHER DETAILS, SEE SCHEDULE O.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$5,807,363ExpenseAmt
Grant$2,833,778GrantAmt
Revenue$0RevenueAmt
DescTREAT ASIA: amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 18 pediatric sites throughout the region, which collaborate on a variety of projects. FOR FURTHER DETAILS, SEE SCHEDULE O.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$4,236,913ExpenseAmt
Grant$0GrantAmt
Revenue$0RevenueAmt
DescEDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. FOR FURTHER DETAILS, SEE SCHEDULE O.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (2 entries)

ExpenseExpenseAmtGrantGrantAmtRevenueRevenueAmtDescDesc
$2,360,664$1,231,676$0GMT Initiative
$2,043,887$131,920$0public policy
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$4,404,551TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant$1,363,596TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue$0TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses$29,589,440TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesYes (true)LobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtYes (true)CollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Temp Or Permanent EndowmentsYes (true)TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecfalseReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesYes (true)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtYes (true)IndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtfalseConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingYes (true)ProfessionalFundraisingInd
Fundraising ActivitiesYes (true)FundraisingActivitiesInd
Gaming ActivitiesfalseGamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsfalseGrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With Officer EntfalseBusinessRlnWithOfficerEntInd
Deductible Non Cash ContriYes (true)DeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityfalseDisregardedEntityInd
Related EntityfalseRelatedEntityInd
Related Organization Ctrl EntfalseRelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document142IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee88EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountYes (true)ForeignFinancialAccountInd
Foreign CountryTHForeignCountryCd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsYes (true)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (true)QuidProQuoContriDisclInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members19GoverningBodyVotingMembersCnt
Independent Voting Member19IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersfalseMembersOrStockholdersInd
Election Of Board MembersfalseElectionOfBoardMembersInd
Decisions Subject To ApprovafalseDecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersfalseLocalChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOYes (true)CompensationProcessCEOInd
Compensation Process OtherYes (true)CompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldAKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldLAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonBRADLEY JENSENPersonNm
Phone2128061703PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1120 WALL STREET 13TH FLOORAddressLine1Txt
Citynew yorkCityNm
State AbbreviationNYStateAbbreviationCd
ZIP100053908ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (40 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
Mathilde Krim PhD
Founding Chairman1.00.0Yes (X)Yes (X)$0$0$0
Kenneth Cole
Chairman of the Board1.00.0Yes (X)Yes (X)$0$0$0
Patricia J Matson
Vice Chairman1.00.0Yes (X)Yes (X)$0$0$0
John C Simons
Vice Chairman1.00.0Yes (X)Yes (X)$0$0$0
Wallace Sheft CPA
Treasurer (thru 09/2015)1.00.0Yes (X)Yes (X)$0$0$0
Mervyn F Silverman MDMPH
Secretary1.00.0Yes (X)Yes (X)$0$0$0
Arlen H Andelson
Trustee1.00.0Yes (X)$0$0$0
Harry Belafonte
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
David Bohnett
Trustee1.00.0Yes (X)$0$0$0
Zev Braun
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
Jonathan S Canno
Trustee1.00.0Yes (X)$0$0$0
Donald Capoccia
Trustee1.00.0Yes (X)$0$0$0
R Martin Chavez PhD
Trustee1.00.0Yes (X)$0$0$0
Jane B Eisner
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
T Ryan Greenawalt
Trustee1.00.0Yes (X)$0$0$0
Regan Hofmann
Trustee1.00.0Yes (X)$0$0$0
Michael J Klingensmith
Trustee1.00.0Yes (X)$0$0$0
Kevin McClatchy
Trustee1.00.0Yes (X)$0$0$0
Michele V McNeill PharmD
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
Edward Milstein
Trustee1.00.0Yes (X)$0$0$0
Cindy Rachofsky
Trustee1.00.0Yes (X)$0$0$0
Vincent A Roberti
Trustee1.00.0Yes (X)$0$0$0
Bill Roedy
Trustee1.00.0Yes (X)$0$0$0
Raymond F Schinazi PhD
Trustee1.00.0Yes (X)$0$0$0
Alan D Schwartz
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
Diana L Taylor
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
Kevin Wendle
Trustee (NON-VOTING)1.00.0Yes (X)$0$0$0
Kevin Frost
Chief Executive Officer40.00.0Yes (X)$520,359$0$86,809
Bradley Jensen
Assistant Treasurer, CFO40.00.0Yes (X)$236,484$0$53,305
John F Logan JD PhD
AssT Sec, Vp, GEN COUNSEL40.00.0Yes (X)$219,864$0$27,414
Rowena Johnston
Asst Secretary, Vice President40.00.0Yes (X)$180,441$0$24,608
Edward Donnelly
Asst Treasurer, Controller40.00.0Yes (X)$145,201$0$21,525
Eric Muscatell
Vice President of Development40.00.0$197,610$0$25,938Yes (X)
AnnMarie Shannahan
Vice President, Public Info.40.00.0$208,911$0$26,630Yes (X)
Gregorio Millet
Vice President, Public Policy40.00.0$112,119$0$7,729Yes (X)
Andrew McInness
Director, Publications40.00.0$148,469$0$47,255Yes (X)
Anthony Ancona
Vice President, Human Resource40.00.0$167,055$0$23,734Yes (X)
Susan Doster
Chief Technology Officer40.00.0$136,579$0$38,133Yes (X)
Bennah Serfaty
Sr Director of CommunicatiON40.00.0$118,344$0$45,064Yes (X)
Raoul Norman Tenazas
Creative Director40.00.0$114,699$0$44,932Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$2,506,135TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$473,076TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K20IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedfalseFormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
AAB PRODUCTION INC
64 ALLEN STREET 5TH FLOORNEW YORKNY10002events production$556,354
JOSH WOODS PRODUCTION
39 WEST 14TH STREET SUITE 504NEW YORKNY10011Events Production$522,240
EIDOLON Communications Inc
15 Maiden Lane Suite 1401NEW YORKNY10038Direct Mail/Consult.$257,093
Changing Our World Inc
220 East 42nd Street 5th FloorNEW YORKNY10017Philanthropic Adviso$210,000
King Company
101 Fifth Avenue 8th FloorNEW YORKNY10003Public Relations$194,450
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K9CntrctRcvdGreaterThan100KCnt
Federated Campaigns$288,202FederatedCampaignsAmt
Fundraising$34,114,106FundraisingAmt
Government Grants$10,220,999GovernmentGrantsAmt
All Other Contributions$11,627,821AllOtherContributionsAmt
Noncash Contributions$631,638NoncashContributionsAmt
Total Contributions$56,251,128TotalContributionsAmt
Total Program Service Revenue$0TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,597,243TotalRevenueColumnAmt
Exclusion$1,597,243ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$55,532TotalRevenueColumnAmt
Exclusion$55,532ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

FieldValueIRS element (for citing)
Real$0RealAmt
Personal$0PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$12,906,804SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$12,975,867SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities-$69,063SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column-$69,063TotalRevenueColumnAmt
Exclusion-$69,063ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$1,871,885FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$34,114,106ContriRptFundraisingEventAmt
Fundraising Direct Expenses$12,158,631FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$10,286,746TotalRevenueColumnAmt
Exclusion-$10,286,746ExclusionAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
FieldValueIRS element (for citing)
Gross Sales Of Inventory$212,642GrossSalesOfInventoryAmt
Cost Of Goods Sold$45,609CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

FieldValueIRS element (for citing)
Total Revenue Column$167,033TotalRevenueColumnAmt
Exclusion$167,033ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDescBusinessBusinessCdTotal Revenue ColumnTotalRevenueColumnAmtExclusionExclusionAmt
LIST RENTALS900099$4,637$4,637
STORE SALES900099$2,411$2,411
MISCELLANEOUS INCOME900099$9,603$9,603
FieldValueIRS element (for citing)
Other Revenue Total$16,651OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$47,731,778TotalRevenueColumnAmt
Exclusion-$8,519,350ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$4,135,665TotalAmt
Program Services$4,135,665ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$5,392,517TotalAmt
Program Services$5,392,517ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$2,507,490TotalAmt
Program Services$1,825,227ProgramServicesAmt
Management And General$324,827ManagementAndGeneralAmt
Fundraising$357,436FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$5,683,653TotalAmt
Program Services$3,788,075ProgramServicesAmt
Management And General$590,969ManagementAndGeneralAmt
Fundraising$1,304,609FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$349,208TotalAmt
Program Services$234,458ProgramServicesAmt
Management And General$41,865ManagementAndGeneralAmt
Fundraising$72,885FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$1,246,045TotalAmt
Program Services$795,117ProgramServicesAmt
Management And General$168,706ManagementAndGeneralAmt
Fundraising$282,222FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$521,172TotalAmt
Program Services$339,231ProgramServicesAmt
Management And General$62,228ManagementAndGeneralAmt
Fundraising$119,713FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$91,139TotalAmt
Program Services$66,900ProgramServicesAmt
Management And General$24,239ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$198,754TotalAmt
Management And General$198,754ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$49,547TotalAmt
Program Services$49,547ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$739,793TotalAmt
Fundraising$739,793FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$249,454TotalAmt
Management And General$249,454ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$2,057,215TotalAmt
Program Services$1,561,504ProgramServicesAmt
Management And General$38,500ManagementAndGeneralAmt
Fundraising$457,211FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$306,946TotalAmt
Program Services$305,602ProgramServicesAmt
Management And General$1,344ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$70,929TotalAmt
Program Services$40,284ProgramServicesAmt
Management And General$6,124ManagementAndGeneralAmt
Fundraising$24,521FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$265,528TotalAmt
Program Services$193,685ProgramServicesAmt
Management And General$32,626ManagementAndGeneralAmt
Fundraising$39,217FundraisingAmt

Royalties RoyaltiesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$1,226,763TotalAmt
Program Services$886,102ProgramServicesAmt
Management And General$144,137ManagementAndGeneralAmt
Fundraising$196,524FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$1,022,253TotalAmt
Program Services$522,799ProgramServicesAmt
Management And General$2,698ManagementAndGeneralAmt
Fundraising$496,756FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$953,805TotalAmt
Program Services$829,472ProgramServicesAmt
Management And General$15,061ManagementAndGeneralAmt
Fundraising$109,272FundraisingAmt

Interest InterestGrp

FieldValueIRS element (for citing)
Total$42TotalAmt
Management And General$42ManagementAndGeneralAmt

Payments To Affiliates PaymentsToAffiliatesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$376,133TotalAmt
Program Services$273,099ProgramServicesAmt
Management And General$44,424ManagementAndGeneralAmt
Fundraising$58,610FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$283,781TotalAmt
Program Services$206,045ProgramServicesAmt
Management And General$33,516ManagementAndGeneralAmt
Fundraising$44,220FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
PROGRAM MATERIALS$6,100,273$6,100,273$0$0
PROGRAM TECHNICAL SUPPORT$878,543$878,543$0$0
POSTAGE & SHIPPING$778,733$357,116$4,661$416,956
PRINTING$710,268$185,971$492$523,805

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$1,380,725TotalAmt
Program Services$622,208ProgramServicesAmt
Management And General$468,811ManagementAndGeneralAmt
Fundraising$289,706FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$37,576,374TotalAmt
Program Services$29,589,440ProgramServicesAmt
Management And General$2,453,478ManagementAndGeneralAmt
Fundraising$5,533,456FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$902,280TotalAmt
Program Services$277,069ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$625,211FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$4,961,745BOYAmt
EOY$18,387,580EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$323,338BOYAmt
EOY$323,338EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$369,693EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$5,045,656BOYAmt
EOY$6,118,590EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

FieldValueIRS element (for citing)
BOY$213,295BOYAmt
EOY$191,382EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$1,475,828BOYAmt
EOY$1,480,222EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$6,133,384LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$3,844,450LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$2,230,700BOYAmt
EOY$2,288,934EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$40,982,916BOYAmt
EOY$39,666,715EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$2,101,105BOYAmt
EOY$1,069,137EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Intangible Assets IntangibleAssetsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$561,388BOYAmt
EOY$1,355,502EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$57,895,971BOYAmt
EOY$71,251,093EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$2,132,495BOYAmt
EOY$3,435,700EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$2,547,120BOYAmt
EOY$3,049,552EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$7,166,426BOYAmt
EOY$10,067,061EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$1,739,583BOYAmt
EOY$1,660,158EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$13,585,624BOYAmt
EOY$18,212,471EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$38,819,754BOYAmt
EOY$48,874,571EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$5,143,351BOYAmt
EOY$3,808,811EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$347,242BOYAmt
EOY$355,240EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$44,310,347BOYAmt
EOY$53,038,622EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$57,895,971BOYAmt
EOY$71,251,093EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss$10,155,404ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst-$1,429,685NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets$2,556OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewfalseAccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Separate Basis Fincl StmtYes (X)SeparateBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredYes (true)FederalGrantAuditRequiredInd
Federal Grant Audit PerformedYes (true)FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$22,876,129CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$33,247,849CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$38,582,579CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$57,556,516CurrentTaxYearMinus1YearAmt
Current Tax Year$56,251,128CurrentTaxYearAmt
Total$208,514,201TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$22,876,129CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$33,247,849CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$38,582,579CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$57,556,516CurrentTaxYearMinus1YearAmt
Current Tax Year$56,251,128CurrentTaxYearAmt
Total$208,514,201TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$3,374,428SubstantialContributorsTotAmt
Public Support Total170$205,139,773PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$951,963CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$897,974CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$755,293CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$804,366CurrentTaxYearMinus1YearAmt
Current Tax Year$1,652,775CurrentTaxYearAmt
Total$5,062,371TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,735,330CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,624,966CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,467,184CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,693,403CurrentTaxYearMinus1YearAmt
Current Tax Year$2,101,178CurrentTaxYearAmt
Total$8,622,061TotalAmt
FieldValueIRS element (for citing)
Total Support$222,198,633TotalSupportAmt
Gross Receipts Rltd Activities$0GrossReceiptsRltdActivitiesAmt
Public Support CY1700.92323PublicSupportCY170Pct
Public Support PY1700.90386PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
Total Grassroots LobbyingTotalGrassrootsLobbyingGrp
Total Direct LobbyingTotalDirectLobbyingGrp
Total Lobbying ExpendTotalLobbyingExpendGrp
Other Exempt Purpose ExpendOtherExemptPurposeExpendGrp
Total Exempt Purpose ExpendTotalExemptPurposeExpendGrp
Lobbying Nontaxable AmountLobbyingNontaxableAmountGrp
Grassroots NontaxableGrassrootsNontaxableGrp
Tot Lbbyng Grassroot Mns Non TxTotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non TxTotLbbyExpendMnsLbbyngNonTxGrp
VolunteersfalseVolunteersInd
Paid Staff Or ManagementYes (true)PaidStaffOrManagementInd
Media AdvertisementsfalseMediaAdvertisementsInd
Mailings MembersfalseMailingsMembersInd
Publications Or BroadcastfalsePublicationsOrBroadcastInd
Grants Other OrganizationsfalseGrantsOtherOrganizationsInd
Direct Contact LegislatorsfalseDirectContactLegislatorsInd
Rallies DemonstrationsfalseRalliesDemonstrationsInd
Other ActivitiesYes (true)OtherActivitiesInd
Other Activities$199,739OtherActivitiesAmt
Total Lobbying Expenditures$199,739TotalLobbyingExpendituresAmt
Not Described Section501c3falseNotDescribedSection501c3Ind
Form4720 Filed4912 TaxfalseForm4720Filed4912TaxInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceLobbying ExpensesFormAndLineReferenceDesc
ExplanationPart II-B The Foundation for AIDS Research developed an Action Agenda to End AIDS that identified critical decisions that need to be made to advance evidence based AIDS policies. We created a variety of issue briefs on topics such as the potential impact of various budget scenarios on global health services, and policy priorities to address the HIV epidemic among gay men in the US. These issue briefs were shared with Capitol Hill staff and members of the Administration. amfAR met regularly with staff to members of Congress and with Administration staff, and we provided input to the Administration on development of the PEPFAR Blueprint for an AIDS Free Generation. amfAR sponsored several briefings on Capitol Hill on AIDS policy and research issues. amfAR uses these briefings as an educational tool.ExplanationTxt

Schedule D IRS990ScheduleD

Art Public Exhibition Amounts ArtPublicExhibitionAmountsGrp

FieldValueIRS element (for citing)
Assets Included$213,703AssetsIncludedAmt
FieldValueIRS element (for citing)
Held Works ArtHeldWorksArtGrp

Collection Used Other Purposes CollectionUsedOtherPurposesGrp

FieldValueIRS element (for citing)
Collection Used Other PurposesYes (X)CollectionUsedOtherPurposesInd
Other PurposesDonated Items, Inventory etc.OtherPurposesDesc
FieldValueIRS element (for citing)
Solicited Assets SaleYes (true)SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$490,979BeginningYearBalanceAmt
Contributions$7,998ContributionsAmt
Investment Earnings Or Losses-$5,941InvestmentEarningsOrLossesAmt
End Year Balance$493,036EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$443,886BeginningYearBalanceAmt
Contributions$6,543ContributionsAmt
Investment Earnings Or Losses$40,550InvestmentEarningsOrLossesAmt
End Year Balance$490,979EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$520,804BeginningYearBalanceAmt
Contributions$3,211ContributionsAmt
Investment Earnings Or Losses$20,742InvestmentEarningsOrLossesAmt
Other Expenditures$100,871OtherExpendituresAmt
End Year Balance$443,886EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$464,356BeginningYearBalanceAmt
Contributions$4,341ContributionsAmt
Investment Earnings Or Losses$52,107InvestmentEarningsOrLossesAmt
End Year Balance$520,804EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$561,083BeginningYearBalanceAmt
Contributions$5,978ContributionsAmt
Investment Earnings Or Losses-$2,705InvestmentEarningsOrLossesAmt
Other Expenditures$100,000OtherExpendituresAmt
End Year Balance$464,356EndYearBalanceAmt
FieldValueIRS element (for citing)
Board Designated Balance EOY0.00000BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY0.72052PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY0.27948TermEndowmentBalanceEOYPct
Endowments Held Unrelated OrgfalseEndowmentsHeldUnrelatedOrgInd
Endowments Held Related OrgfalseEndowmentsHeldRelatedOrgInd
LandLandGrp
BuildingsBuildingsGrp

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$2,215,917OtherCostOrOtherBasisAmt
Depreciation$877,847DepreciationAmt
Book Value$1,338,070BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$309,029OtherCostOrOtherBasisAmt
Depreciation$279,288DepreciationAmt
Book Value$29,741BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$3,608,438OtherCostOrOtherBasisAmt
Depreciation$2,687,315DepreciationAmt
Book Value$921,123BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$2,288,934TotalBookValueLandBuildingsAmt
Federal Income Tax Liability$0FederalIncomeTaxLiabilityAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDescAmtAmt
LONG TERM LEASE LIABILITY$1,513,795
SECTION 457 RETIREMENT LIABILITIES$146,363
FieldValueIRS element (for citing)
Total Liability$1,660,158TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$46,610,198TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst-$1,429,685NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$305,549DonatedServicesAndUseFcltsAmt
Other Revenue$2,556OtherRevenueAmt
Revenue Not Reported-$1,121,580RevenueNotReportedAmt
Revenue Subtotal$47,731,778RevenueSubtotalAmt
Total Revenue Per Form990$47,731,778TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$37,881,923TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$305,549DonatedServicesUseFcltsAmt
Expenses Not Reported$305,549ExpensesNotReportedAmt
Expenses Subtotal$37,576,374ExpensesSubtotalAmt
Total Expenses Per Form990$37,576,374TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (4 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
EndowmentsPart V, Line 4 AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors.
FIN 48Income taxes Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement. This guidance provides that the tax effects from an uncertain tax position can only be recognized in the financial statements if the position is "more-likely-than-not" to be sustained if the position were to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended SEPTEMBER 30, 2012, 2013, 2014 and 2015 are still open to audit for both federal and state purposes. amfAR has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements.
reconciliation of revenuepart XI, Line 2d change in value for third party trust $2,556
Collections of Art, Historical Treasures, or other similar assetsPart III, Line 4 AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them.

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (11 entries)

RegionRegionTxtType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmtOfficesOfficesCntEmployeeEmployeeCnt
Central America and the CaribbeanGrantmakingN/A$35,000
East Asia and the PacificGrantmakingN/A$3,258,027
Europe (Including Iceland and Greenland)GrantmakingN/A$874,724
North AmericaGrantmakingN/A$610,913
South AmericaGrantmakingN/A$398,624
South AsiaGrantmakingN/A$100,684
Sub-Saharan AfricaGrantmakingN/A$114,545
East Asia and the PacificProgram ServicesTHERAPEUTICS, TRAINING$5,108,145122
Europe (Including Iceland and Greenland)FundraisingN/A$12,944,557
South AmericaFundraisingN/A$549,245
South AsiaFundraisingN/A$1,943,338
FieldValueIRS element (for citing)
Subtotal Offices1SubtotalOfficesCnt
Subtotal Employees22SubtotalEmployeesCnt
Total Office1TotalOfficeCnt
Total Employee22TotalEmployeeCnt
Subtotal Spent$25,937,802SubtotalSpentAmt
Total Spent$25,937,802TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (70 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxt
Caribbean/Central AmericaGMT INITIATIVE$25,000wire transfe
East Asia/PacificBASIC RESEARCH$60,000wire transfe
East Asia/PacificBASIC RESEARCH$47,240wire transfe
East Asia/PacificBASIC RESEARCH$124,983wire transfe
East Asia/PacificGMT INITIATIVE$25,000wire transfe
East Asia/PacificGMT INITIATIVE$25,000wire transfe
East Asia/PacificGMT INITIATIVE$300,000wire transfe
East Asia/PacificGMT INITIATIVE$13,271wire transfe
East Asia/PacificTREAT ASIA$47,338wire transfe
East Asia/PacificTREAT ASIA$985,866wire transfe
East Asia/PacificTREAT ASIA$20,320wire transfe
East Asia/PacificTREAT ASIA$46,800wire transfe
East Asia/PacificTREAT ASIA$32,890wire transfe
East Asia/PacificTREAT ASIA$5,625wire transfe
East Asia/PacificTREAT ASIA$7,500wire transfe
East Asia/PacificTREAT ASIA$6,000wire transfe
East Asia/PacificTREAT ASIA$6,450wire transfe
East Asia/PacificTREAT ASIA$6,300wire transfe
East Asia/PacificTREAT ASIA$6,375wire transfe
East Asia/PacificTREAT ASIA$5,775wire transfe
East Asia/PacificTREAT ASIA$71,092wire transfe
East Asia/PacificTREAT ASIA$32,607wire transfe
East Asia/PacificTREAT ASIA$127,215wire transfe
East Asia/PacificTREAT ASIA$11,200wire transfe
East Asia/PacificTREAT ASIA$9,500wire transfe
East Asia/PacificTREAT ASIA$66,888wire transfe
East Asia/PacificTREAT ASIA$107,092wire transfe
East Asia/PacificTREAT ASIA$93,266wire transfe
East Asia/PacificTREAT ASIA$29,354wire transfe
East Asia/PacificTREAT ASIA$15,550wire transfe
East Asia/PacificTREAT ASIA$15,450wire transfe
East Asia/PacificTREAT ASIA$11,475wire transfe
East Asia/PacificTREAT ASIA$46,717wire transfe
East Asia/PacificTREAT ASIA$15,050wire transfe
East Asia/PacificTREAT ASIA$20,000wire transfe
East Asia/PacificTREAT ASIA$20,000wire transfe
East Asia/PacificTREAT ASIA$20,000wire transfe
East Asia/PacificTREAT ASIA$19,700wire transfe
East Asia/PacificTREAT ASIA$73,650wire transfe
East Asia/PacificTREAT ASIA$20,000wire transfe
East Asia/PacificTREAT ASIA$7,310wire transfe
East Asia/PacificTREAT ASIA$71,880wire transfe
East Asia/PacificTREAT ASIA$10,000wire transfe
East Asia/PacificTREAT ASIA$12,000wire transfe
EuropeBASIC RESEARCH$75,000wire transfe
EuropeBASIC RESEARCH$75,000wire transfe
EuropeBASIC RESEARCH$60,000wire transfe
EuropeBASIC RESEARCH$81,852wire transfe
EuropeBASIC RESEARCH$443,407wire transfe
EuropeBASIC RESEARCH$74,798wire transfe
EuropeBASIC RESEARCH$59,983wire transfe
EuropeBASIC RESEARCH$20,000wire transfe
EuropeBASIC RESEARCH$9,362wire transfe
North America (excl USA)BASIC RESEARCH$44,444wire transfe
North America (excl USA)BASIC RESEARCH$166,391wire transfe
North America (excl USA)BASIC RESEARCH$400,078wire transfe
South AmericaGMT INITIATIVE$292,226wire transfe
South AmericaGMT INITIATIVE$96,398wire transfe
South AsiaPUBLIC POLICY$20,000wire transfe
South AsiaPUBLIC POLICY$21,025wire transfe
South AsiaTREAT ASIA$19,450wire transfe
South AsiaTREAT ASIA$11,595wire transfe
South AsiaTREAT ASIA$22,762wire transfe
South AsiaTREAT ASIA$9,047wire transfe
Sub-Saharan AfricaGMT INITIATIVE$25,000wire transfe
Sub-Saharan AfricaPREVENTION SCIENCE OUTREACH$25,000wire transfe
Sub-Saharan AfricaPUBLIC POLICY$39,945wire transfe
Sub-Saharan AfricaPUBLIC POLICY$10,000wire transfe
East Asia and the PacificTREAT ASIA$42,600wire transfe
East Asia and the PacificTREAT ASIA$591,568wire transfe
FieldValueIRS element (for citing)
Total501c3 Org70Total501c3OrgCnt
Transfer To Foreign CorpfalseTransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipfalseForeignCorpOwnershipInd
Passive Foreign Investmest CofalsePassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
Foreign ActivitiesPart I, Line 2 International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period.
foreign activitiesPart I, Line 3, Column D The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives.
Foreign Activities - Status of GranteesThe Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 149 charities supported are presumed to be the equivalent of U.S. charities.

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
Phone SolicitationsYes (X)PhoneSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Solicitation Of Govt GrantsYes (X)SolicitationOfGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (true)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (5 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndGross ReceiptsGrossReceiptsAmtRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
aab productions INC
387 Grant Street Suite K705New YorkNY10002events productionfalse$23,129,015$614,956$22,514,059
EIDOLON COMMUNICATIONS INC
15 Maiden Lane Suite 1401New YorkNY10038direct mailfalse$2,131,227$270,650$1,860,577
public interest communications
7700 Leesburg PikeFalls ChurchVA22043tele marketingfalse$18,728$32,099-$13,371
Donor Services Group LLC
6715 Sunset BlvdHollywoodCA90028Tele marketingfalse$100$6,588-$6,488
Josh Woods Production
245 W 29th StreetNew YorkNY10001Special event prod.false$7,952,320$528,000$7,424,320
FieldValueIRS element (for citing)
Total Gross Receipts$33,231,390TotalGrossReceiptsAmt
Total Retained By Contractors$1,452,293TotalRetainedByContractorsAmt
Total Net To Organization$31,779,097TotalNetToOrganizationAmt
Licensed StatesALLicensedStatesCd
Licensed StatesAKLicensedStatesCd
Licensed StatesARLicensedStatesCd
Licensed StatesCALicensedStatesCd
Licensed StatesCOLicensedStatesCd
Licensed StatesCTLicensedStatesCd
Licensed StatesDCLicensedStatesCd
Licensed StatesFLLicensedStatesCd
Licensed StatesGALicensedStatesCd
Licensed StatesHILicensedStatesCd
Licensed StatesILLicensedStatesCd
Licensed StatesKSLicensedStatesCd
Licensed StatesKYLicensedStatesCd
Licensed StatesLALicensedStatesCd
Licensed StatesMELicensedStatesCd
Licensed StatesMDLicensedStatesCd
Licensed StatesMALicensedStatesCd
Licensed StatesMILicensedStatesCd
Licensed StatesMNLicensedStatesCd
Licensed StatesMSLicensedStatesCd
Licensed StatesMOLicensedStatesCd
Licensed StatesNVLicensedStatesCd
Licensed StatesNHLicensedStatesCd
Licensed StatesNJLicensedStatesCd
Licensed StatesNMLicensedStatesCd
Licensed StatesNYLicensedStatesCd
Licensed StatesNCLicensedStatesCd
Licensed StatesNDLicensedStatesCd
Licensed StatesOHLicensedStatesCd
Licensed StatesOKLicensedStatesCd
Licensed StatesORLicensedStatesCd
Licensed StatesPALicensedStatesCd
Licensed StatesRILicensedStatesCd
Licensed StatesSCLicensedStatesCd
Licensed StatesTNLicensedStatesCd
Licensed StatesTXLicensedStatesCd
Licensed StatesUTLicensedStatesCd
Licensed StatesVALicensedStatesCd
Licensed StatesWALicensedStatesCd
Licensed StatesWVLicensedStatesCd
Licensed StatesWILicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1CANNESEvent1Nm
Gross Receipts Event1$15,990,176GrossReceiptsEvent1Amt
Charitable Contri Event1$15,534,176CharitableContriEvent1Amt
Gross Revenue Event1$456,000GrossRevenueEvent1Amt
Rent Facility Costs Event1$1,166,241RentFacilityCostsEvent1Amt
Food And Beverage Event1$164,025FoodAndBeverageEvent1Amt
Entertainment Event1$1,171,125EntertainmentEvent1Amt
Other Direct Expenses Event1$2,236,215OtherDirectExpensesEvent1Amt
Event2DALLASEvent2Nm
Gross Receipts Event2$4,102,963GrossReceiptsEvent2Amt
Charitable Contri Event2$3,978,678CharitableContriEvent2Amt
Gross Revenue Event2$124,285GrossRevenueEvent2Amt
Rent Facility Costs Event2$261,520RentFacilityCostsEvent2Amt
Food And Beverage Event2$155,135FoodAndBeverageEvent2Amt
Entertainment Event2$73,913EntertainmentEvent2Amt
Other Direct Expenses Event2$554,882OtherDirectExpensesEvent2Amt
Other Events Total16OtherEventsTotalCnt
Gross Receipts Other Events$15,892,852GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$14,601,252CharitableContriOtherEventsAmt
Gross Revenue Other Events$1,291,600GrossRevenueOtherEventsAmt
Rent Fclty Costs Other Events$495,405RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events$960,466FoodAndBeverageOtherEventsAmt
Entertainment Other Events$2,081,591EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events$2,838,113OthDirectExpnssOtherEventsAmt
Gross Receipts Total$35,985,991GrossReceiptsTotalAmt
Charitable Contributions Tot$34,114,106CharitableContributionsTotAmt
Gross Revenue Total Events$1,871,885GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events$1,923,166RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events$1,279,626FoodAndBeverageTotalEventsAmt
Entertainment Total Events$3,326,629EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$5,629,210OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$12,158,631DirectExpenseSummaryEventsAmt
Net Income Summary-$10,286,746NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSchedule G, Part IFormAndLineReferenceDesc
ExplanationThe Foundation for AIDS Research actually paid out $739,793 in fundraising expenses for the year ending September 30, 2015. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $1,452,293. Of that $1,452,293, only $739,793 was paid for fundraising services, the remaining $712,500 was paid for event production services. In the interests of clarity, the foundation would also like to make clear that the compensation reported as having been paid to the professional fundraisers reported on Schedule G is reported on a fiscal year basis. Some of those same fundraisers are reported on the foundation's top 5 highest paid independent contractors list (in Schedule O). In compliance with the instructions to the Form 990, compensation reported for Part VII (and listed in Schedule O) is reported on a calendar year basis. Accordingly, amounts on Part VII and Schedule G will not reconcile.ExplanationTxt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Recipient Table RecipientTable (33 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtPurpose Of GrantPurposeOfGrantTxtAddress Line1ForeignAddress/AddressLine1TxtCityForeignAddress/CityNmCountryForeignAddress/CountryCd
Beth Israel Deaconess Medical Center
330 Brookline AvenueBostonMA02215042103881501(c)(3)$124,497BASIC RESEARCH
Blood Systems Inc
270 Masonic AvenueSan FranciscoCA941184417860098929501(c)(3)$60,000BASIC RESEARCH
Case Western Reserve University
10900 Euclid Avenue LC 4930ClevelandOH44106341018992501(c)(3)$321,508BASIC RESEARCH
Charities Aid Foundation of America (CAF America)
King Street Station 1800 Diagonal RAlexandriaVA223148931431634280501(c)(3)$301,163PREVENTION SCIENCE OUTREACH
Cold Spring Harbor Laboratory
1 Bungotwn RoadCold Spring HaborNY11724112013303501(c)(3)$12,000BASIC RESEARCH
Colorado State University
408 University Svcs CenterFort CollinsCO805232002846000545501(c)(3)$188,128BASIC RESEARCH
Dana-Farber Cancer Institute Inc
450 Brookline Avenue CLS 1017BostonMA02215042263040501(c)(3)$28,538BASIC RESEARCH
Emory University
1599 Clifton RdAtlantaGA303224250580566256501(c)(3)$342,000BASIC RESEARCH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N C2-187SeattleWA98109237156071501(c)(3)$15,626BASIC RESEARCH
Icahn School of Medicine at Mount Sinai
One Gustave Levy PlaceNew YorkNY10029136171197501(c)(3)$60,000BASIC RESEARCH
Intercambios Puerto Rico
660731885501(c)(3)$20,000PUBLIC POLICY165 Calle Diego Zalduondo AltosFajardoRQ
Johns Hopkins University
733 N Broadway MRB Suite 117BaltimoreMD21205520595110501(c)(3)$634,872BASIC RESEARCH, gmt initiative, treat asia
Massachusetts General Hospital
55 Fruit StreetBostonMA02114042697983501(c)(3)$177,482BASIC RESEARCH
Mount Sinai Beth Israel
First Avenue at 16th StreetNew YorkNY10003135564934501(c)(3)$22,500PUBLIC POLICY
New Hope for Cambodian Children
PO Box 690597KilleenTX76549205301015501(c)(3)$50,000TREAT ASIA
New York University
545 First Avenue Greenberg Hall SCNew YorkNY10016135562308501(c)(3)$75,000BASIC RESEARCH
Northwestern University
303E Superior Street Rm 9-159ChicagoIL60611362167817501(c)(3)$55,385BASIC RESEARCH
Oregon Health and Science University
3181 SW Sam Jackson Park RoadPortlandOR97239931176109501(c)(3)$179,872BASIC RESEARCH
Regents of the University of California San Franc
3333 California Street Suite 315San FranciscoCA94143946036493501(c)(3)$245,000BASIC RESEARCH
The George Washington University
2121 I Street NW Suite 601WashingtonDC20052530196584501(c)(3)$22,498BASIC RESEARCH
The Rockefeller University
1230 York AvenueNew YorkNY10065131624158501(c)(3)$1,075,000BASIC RESEARCH
The Scripps Research Institute
10550 North Torrey Pines RoadLa JollaCA92037330435954501(c)(3)$15,626BASIC RESEARCH
The University of North Carolina at Chapel Hill
104 Airport Drive CB 1350Chapel HillNC27599566001393501(c)(3)$86,666BASIC RESEARCH
Trustees of the University of Pennsylvania
422 Curie BlvdPhiladelphiaPA19104231352685501(c)(3)$75,000BASIC RESEARCH
University of California Los Angeles
11000 Kinross Avenue Suite 211Los AngelesCA90095956006143501(c)(3)$225,000BASIC RESEARCH
University of Nebraska-Lincoln
151 Whittier Research Center 2200LincolnNE685830861470049123501(c)(3)$60,000BASIC RESEARCH
University Of Pittsburgh
123 University PlacePittsburghPA15213250965591501(c)(3)$163,804GMT INITIATIVE
University of Southern California
2001 North Soto StreetLos AngelesCA900899235951642394501(c)(3)$90,000BASIC RESEARCH
University of Utah
15 North Medical Drive East JMRB 21Salt Lake CityUT841125650876000525501(c)(3)$60,000BASIC RESEARCH
University of Washington
4333 Brooklyn Ave NE Box 359472SeattleWA981959472916001537501(c)(3)$60,000BASIC RESEARCH
Vaccine and Gene Therapy Institute Florida
9801 SW Discovery WayPort St LucieFL34987364631835501(c)(3)$505,665BASIC RESEARCH
Veterans Medical Research Foundation
3350 La Jolla Village Drive 151ASan DiegoCA921610002330189397501(c)(3)$60,000BASIC RESEARCH
Worldwide Orphans Foundation
515 Valley Street Suite 201MaplewoodNJ07040133968225501(c)(3)$15,000TREAT ASIA
FieldValueIRS element (for citing)
Total501c3 Org33Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceGrants and AssistanceFormAndLineReferenceDesc
ExplanationPart I, Line 2 amfAR Provides grants and fellowships to independent not-for-profit organizations through a peer-review process. Grant applications are first reviewed by the Foundation's volunteer scientific advisory committee, which comprises recognized experts in the medical, scientific, and social sciences disciplines relevant to HIV and AIDS. The scientific advisory committee then sends its evaluations to one of the three committees (research, global initiatives or public policy) of the Foundation's program board, which serves in an advisory capacity to the Board of Trustees. After a program committee has completed its review of the applications, it presents its funding recommendations to amfAR's executive committee and/or the full Board of Trustees for final approval and funding authorization. Grants and fellowships are payable over a one-to-three-year period, and are revocable at amfAR's option if the recipient's performance or use of funds is not consistent with the terms of the grant or fellowships. In certain cases, the actual amounts paid under grants and fellowship awards may be less than the original award if the recipient does not use the full amount awarded. Therefore, a reserve for unexpended grants and fellowships has been recorded. Subawards are grants awarded to not-for-profit organizations to support the costs of collaboration and participation in HIV/AIDS-related research projects for which amfAR has secured restricted funds. Subawards are payable over a one-year period, although advance payments, in full or in part, may be issued following execution of the subaward agreement. Subawards are contingent upon the availability of funds and are revocable if the recipients' performance or use of funds is not consistent with the subaward terms.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentfalseSeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (true)SupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsfalseAnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Kevin Frost
Chief Executive Officer$394,276$0$0$0$126,083$0$35,700$0$51,109$0$607,168$0$59,500$0
Bradley Jensen
Assistant Treasurer, CFO$236,484$0$0$0$0$0$16,732$0$36,573$0$289,789$0$0$0
John F Logan JD PhD
AssT Sec, Vp, GEN COUNSEL$219,864$0$0$0$0$0$15,500$0$11,914$0$247,278$0$0$0
Rowena Johnston
Asst Secretary, Vice President$180,441$0$0$0$0$0$12,694$0$11,914$0$205,049$0$0$0
Edward Donnelly
Asst Treasurer, Controller$145,201$0$0$0$0$0$10,596$0$10,929$0$166,726$0$0$0
Eric Muscatell
Vice President of Development$197,610$0$0$0$0$0$14,024$0$11,914$0$223,548$0$0$0
Annette Sohn
Vice President, TREAT Asia PGM$225,322$0$0$0$0$0$15,373$0$6,032$0$246,727$0$0$0
AnnMarie Shannahan
Vice President, Public Info.$208,911$0$0$0$0$0$14,716$0$11,914$0$235,541$0$0$0
Andrew McInness
Director, Publications$148,469$0$0$0$0$0$10,682$0$36,573$0$195,724$0$0$0
Anthony Ancona
Vice President, Human Resource$167,055$0$0$0$0$0$11,828$0$11,906$0$190,789$0$0$0
Susan Doster
Chief Technology Officer$136,579$0$0$0$0$0$9,940$0$28,193$0$174,712$0$0$0
Bennah Serfaty
Sr Director of CommunicatiON$118,344$0$0$0$0$0$8,491$0$36,573$0$163,408$0$0$0
Raoul Norman Tenazas
Creative Director$114,699$0$0$0$0$0$8,359$0$36,573$0$159,631$0$0$0

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceCompensationFormAndLineReferenceDesc
ExplanationPart I, Line 4 Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan. In calendar year 2014, Amfar contributed $60,000 into Mr. Frost's non-qualified retirement plan. This amount is not reported in Schedule J, Part II, Column (c) because the contributed amount was distributed to Mr. Frost within the same calendar year. Included in Schedule J column (b)(iii) is Mr. Frost's 2014 employer-funded 457(f) contribution of $60,000 plus payouts of previously contributed employer-funded 457(f) contributions (and earnings thereon). In Schedule J, part II, column (f), amfar is reporting $59,500 of 457(f) contributions that were recorded as deferred compensation on a previously filed Form 990.ExplanationTxt

Schedule M IRS990ScheduleM

FieldValueIRS element (for citing)
Works Of ArtWorksOfArtGrp
Art Historical TreasuresArtHistoricalTreasuresGrp
Art Fractional InterestArtFractionalInterestGrp
Books And PublicationsBooksAndPublicationsGrp
Clothing And Household GoodsClothingAndHouseholdGoodsGrp
Cars And Other VehiclesCarsAndOtherVehiclesGrp
Boats And PlanesBoatsAndPlanesGrp
Intellectual PropertyIntellectualPropertyGrp

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution20ContributionCnt
Noncash Contributions Rpt F990$631,638NoncashContributionsRptF990Amt
Method Of Determining Revenuessales priceMethodOfDeterminingRevenuesTxt
FieldValueIRS element (for citing)
Securities Closely Held StockSecuritiesCloselyHeldStockGrp
Secur Prtnrshp Trust IntrstsSecurPrtnrshpTrustIntrstsGrp
Securities MiscellaneousSecuritiesMiscellaneousGrp
Qualified Contrib Hist StructQualifiedContribHistStructGrp
Qualified Contrib OtherQualifiedContribOtherGrp
Real Estate ResidentialRealEstateResidentialGrp
Real Estate CommercialRealEstateCommercialGrp
Real Estate OtherRealEstateOtherGrp
CollectiblesCollectiblesGrp
Food InventoryFoodInventoryGrp
Drugs And Medical SuppliesDrugsAndMedicalSuppliesGrp
TaxidermyTaxidermyGrp
Historical ArtifactsHistoricalArtifactsGrp
Scientific SpecimensScientificSpecimensGrp
Archaeological ArtifactsArchaeologicalArtifactsGrp
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (true)ReviewProcessUnusualNCGiftsInd
Third Parties UsedfalseThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceForm 990, Schedule M, line 31FormAndLineReferenceDesc
ExplanationTo the extent that amFAR receives non-standard contributions, the organization's policy is to liquidate those items into cash for eventual use in support of the organization's mission.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
Program Service Accomplishments(1)Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the U.S. National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the pursuit of a cure for HIV/AIDS. Countdown to a Cure for AIDS In February 2015, amfAR outlined a $100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy represents an unprecedented expansion of amfAR's grant making and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development. It is structured to provide sustained support for a wide range of studies that advance both emerging and established ideas. The strategy comprises the following components: - amfAR Institute for HIV Cure Research Launched at the end of 2015 at the University of California, San Francisco, the Institute will be the cornerstone of amfAR's cure research efforts and will be supported by a $20 million grant over five years. - Innovation Grants These two-year awards of up to $200,000 each will enable researchers to test innovative ideas supported by limited preliminary data. - Impact Grants These grants of up to $2 million each over four years will support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure. - Investment Grants Aimed at recruiting the experience and expertise of scientists from outside the field of HIV, these $1 million grants will be awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience or inflammatory disease that can directly inform efforts to cure HIV. - ARCHE Launched in 2010, the amfAR Research Consortium on HIV Eradication, or ARCHE, supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. - Opportunity Fund This funding mechanism will enable amfAR to respond quickly to emerging and unforeseen research opportunities. Innovation Grants In February 2015, amfAR's Board of Trustees approved the first round of 11 Innovation Grants totaling close to $2 million. Among them is a study by Dr. Benjamin Burwitz of Oregon Health and Science University in Portland that could help determine the precise mechanism of action that led to the first and only known HIV cure in the "Berlin Patient." Dr. Burwitz and colleagues plan to generate a non-human primate that will allow the testing of many hypotheses concerning the Berlin patient's cure, as well as, for example, gene therapy interventions designed to cure HIV. Another of these Innovation Grants was underwritten by generationCURE, a group of young professionals dedicated to supporting amfAR's cure-focused research. This inaugural $180,000 generationCURE grant was awarded to Dr. Brad Jones, assistant professor at George Washington University's Research Center for the Cure and Eradication of HIV, who is studying whether a novel combination therapy can eradicate the latent reservoirs of HIV that present a major barrier to finding a cure. Impact Grants In July amfAR awarded its first ever four-year grants at $2 million each. A team of researchers led by Dr. Dan Barouch of Beth Israel Deaconess Medical Center in Boston is investigating the ability of combinations of antibodies to specifically kill latently infected cells in the lab, in monkeys, and then in people. The researchers will test two promising antibodies alone and together, in combination with a newly described drug that can "shock" the virus out of latently infected cells and possibly enhance the ability of the antibodies to locate the infected cells. Dr. Timothy Henrich of the University of California, San Francisco, and his colleagues are pursuing a novel intervention aimed at restoring normal immune function in people with HIV. The team is testing whether the transplant drug, sirolimus, can increase the activity of beneficial components of the immune system while suppressing detrimental activity of other components. The team will thoroughly assess the drug's activities before moving on to test the drug on persistent HIV reservoirs in people. Using an approach that has already proved successful in cancer therapy, Dr. Sharon Lewin of the University of Melbourne, Australia, is exploring whether drugs that block so-called immune checkpoints can also be effective against HIV. Researchers theorize that the immune system cannot eliminate infected cells because of immune checkpoints, a set of mechanisms that limit the duration of an immune response so that the immune system does not become exhausted. Dr. Lewin and her team will test two drugs, alone and together, for their ability to reverse immune exhaustion and restore the ability of the immune system to eliminate infected cells. ARCHE In February the board approved a $1.5 million ARCHE (amfAR Research Consortium on HIV Eradication) grant to support a team of researchers from Rockefeller University in New York, Aarhus University Hospital in Denmark, and the University Hospital of Cologne, Germany. The researchers are testing the ability of the cancer drug Romidepsin, which has been shown to be effective at "shocking" HIV out of hiding, combined with an antibody to eliminate infected cells and thus reduce the size of the persistent HIV reservoir. Mathilde Krim Fellowships In October 2014, amfAR awarded an eighth round of Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. Dr. Stylianos Bournazos of the Rockefeller University in New York is studying a range of antibody functions that could inform future vaccine design. Drs. David Schwefel of MRC National Institute for Medical Research in London and Spyridon Stavrou of the University of Pennsylvania are focusing on antiviral defenses within cells called restriction factors, which HIV has evolved to overcome, thus protecting itself from destruction. And Dr. Henning Hoffman of New York University is studying harmful overactivity of the immune system often caused by HIV infection, which can increase the risk of heart disease and other conditions. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, 44 scientific publications resulted from amfAR-funded research. The Effects of Early Treatment Writing in the November 2014 issue of the Journal of Infectious Diseases, amfAR grantees Dr. Katherine Luzuriaga of the University of Massachusetts Medical School, Dr. Deborah Persaud of Johns Hopkins University, and colleagues reported on eight children who were perinatally infected with HIV and then followed for up to 18 years. Four were treated with ART shortly after birth, while the other four, in keeping with treatment guidelines in place at the time of their infection, did not receive ART until 6 to 15 years of age. Most striking was the fact that all four treated early had lower levels of proviral DNA-one measure of HIV reservoir size-along with decreased T-cell activation and absent or minimal anti-HIV immune responses, which is another indication of vanishingly small levels of virus in their bodies. Drs. Luzuriaga, Persaud, and associates concluded that "life-long therapy may not be necessary for all individuals, particularly those who initiate cART during primary infection." When Is the Reservoir Established? Writing in the January issue of Current Opinion in HIV and AIDS, Dr. Nicolas Chomont of the Vaccine and Gene Therapy Institute in Florida and associates from the U.S. Military HIV Research Program and t
Program Service Accomplishments (2)Line 4b: TREAT ASIA: amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 18 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists published 28 publications in peer-reviewed medical journals in FY2015. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from approximately 9,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. TAHOD-Lite While TAHOD continues to be an essential resource for assessing treatment outcomes in Asian populations, its model of in-depth data collection limits the size of the cohort to a subset of those living with HIV who are cared for at the participating clinics. In FY2015, TREAT Asia launched a new database called TAHOD-Lite that includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. In FY2015, the IeDEA consortium launched a new study aiming to develop and validate a standardized tool to measure and better understand adherence among young people. The study is building on research already done by an IeDEA site in Kenya. TREAT Asia is working with HIV-NAT at the Thai Red Cross AIDS Research Centre to conduct a Thai component. The study will employ and evaluate a brief standard questionnaire that can accurately assess young people's adherence to treatment. It will also examine current adherence among children at the three participating IeDEA sites in Kenya, South Africa, and Thailand, evaluate factors that increase the risk of non-adherence, and assess the impact of non-adherence on treatment failure and clinic dropout. TREAT Asia Pediatric Network TREAT Asia's Pediatric Network includes 18 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database and includes data from approximately 5,500 pediatric patients in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. TREAT Asia has been following a prospective cohort study of 248 HIV-infected adolescents to evaluate multiple social, cultural, and behavioral factors that affect ART adherence using an audio computer-assisted self-interview (ACASI) instrument at nine TApHOD sites in Malaysia, Thailand, and Vietnam. Among the study findings were that adolescents with effective virologic suppression were less likely to report high-risk sexual behaviors, such as inconsistent condom use. This emphasizes the need to promote and support strategies to achieve viral suppression as a key priority for adolescents who are struggling to remain adherent to ART. This study was supported by the AIDS Life Foundation. Additional Adolescent Research In FY2015, TREAT Asia conducted and continued several studies aimed at improving the health and well-being of adolescents living with HIV. HIV-NAT/Thai Red Cross AIDS Research Centre, in collaboration with three other clinical sites in Thailand, conducted a study of whether technology-based interventions, in this case short messaging service (SMS) reminders, can increase adherence to antiretroviral therapy among adolescents. This study received support from ViiV Healthcare. TREAT Asia conducted the third year of its study to evaluate the natural history of HPV infection and risk factors for HPV acquisition and persistence among perinatally HIV-infected individuals compared to uninfected female and male adolescents in Thailand and Vietnam. The findings, which were presented at the International Workshop on HIV Pediatrics in July 2015, support the need for greater integration of preventive sexual health services into HIV care programs for young women with HIV, and more effective linkages between existing healthcare programs supporting adolescents. This study was supported by the AIDS Life Foundation. Expanding Pre-Exposure Prophylaxis (PrEP) for HIV in Thailand In 2015, in an effort to enhance national HIV prevention efforts, the Thai Red Cross AIDS Research Centre and Adam's Love, Thailand's leading Internet and social media-based HIV outreach initiative, began working on two groundbreaking efforts to bring oral pre-exposure prophylaxis (PrEP) to MSM in Thailand. Both projects are supported in part by TREAT Asia. Adam's Love's PrEP-30 campaign is Thailand's first major effort to spread awareness about PrEP and how it works and encourage MSM who are at higher risk of HIV infection to consider using it. Dr. Nittaya Phanuphak is leading a Thai Red Cross study on the uptake and efficacy of PrEP among Thai MSM and hopes the findings from her research will encourage the Thai government to cover the cost of PrEP under Thailand's national health insurance. Exploring Links Between HIV and Cancer Because MSM living with HIV are twice as likely as those without HIV to develop the anal cancer associated with human papillomavirus (HPV), the Anonymous Clinic of the Thai Red Cross AIDS Research Centre, a TREAT Asia network member in Bangkok, started screening its patients for anal precancers. Using funding from amfAR's GMT Initiative, they purchased the high-resolution anoscopy microscope necessary to diagnose and treat both anal warts and precancerous anal lesions, and began providing anal Pap smears and treatment free of charge. This not only benefited their patients, it also generated some of the first data about HPV and anal neoplasia-the final stage the lesions reach before developing into cancer-among MSM in a resource-limited setting in the Asia-Pacific. With support from TREAT Asia, the AIDS Life Foundation, the U.S. National Institutes of Health, and the University of California, San Francisco, three additional TREAT Asia sites in Indonesia and Malaysia have established similar programs. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In 2015, with support from ViiV Healthcare's new Positive Action for Adolescents program, TREAT Asia launched a program called Youth ACATA (Asia Community for AIDS Treatment and Advocacy) in an effort to mobilize HIV-positive youth across the region. It held three Youth ACATA workshops for young people living with HIV from Cambodia, Indonesia, Thailand, and Vietnam in an effort to mobilize youth HIV advocacy across the region, among other trainings. TREAT Asia also released a policy brief urging governments, public health authorities, healthcare providers, and civil society in Asia to address persistent gaps in women's access to reproductive health services, especially for women living with HIV in the region. Sexual and Reproductive Health of HIV-Positive Women in Asia: A Policy Framework for the Future provides recommendations aimed at closing gaps in the delivery of HIV prevention and care in Asia. In August 2015, Adam's Love launched Adam's Love Taiwan, its fourth country-specific HIV outreach campaign targeting at-risk populations through its unique online edutainment approach that combines educational HIV resources with videos and social media posts from national celebrities. (Adam's Love is supported by ViiV and amfAR, and sponsored by the Thai Red Cross AIDS Research Centre.) Adam's Love's other three edutainment projects-Adam's Love Thailand and TemanTeman.org Indonesia and Malaysia-have all been highly successful, garnering a total of nearly three million unique visitors to their websites. Adam's Love is partnering with three additional GMT-friendly clinics in the country to help individuals in Taiwan access convenient, discrimination-free VCT services. They aim to continue to expand across the region, with plans to launch websites in South Korea in 2016 and Japan by 2017. In addition, TREAT Asia continued to publish lay-language articles on AIDS research, policy, and community issues facing the TREAT Asia network and the Asia-Pacific as a whole. It also
Program Service Accomplishments (3)Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 45,000 people; the TREAT Asia Report, an e-mail newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 100,000 people. The Foundation's website features news, interviews, blog posts, and other original articles covering science, policy, the global epidemic, and amfAR programs and activities. The website attracts an average 30,000 visitors per month. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page and live tweeted and posted images on Instagram from fundraising and program events. amfAR has 67,000 likes on Facebook, 35,400 Twitter followers, and more than 81,000 Instagram followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS-related press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR staff and spokespeople-were carried in numerous media outlets, including the New York Times, The Wall Street Journal, The Washington Post, and The Huffington Post, and news agencies such as the Associated Press, CNN, Bloomberg News, and Reuters. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone. In FY2015 Scarlett Johansson donated her time to record a voiceover for an amfAR video promoting its Countdown to a Cure for AIDS initiative. Other celebrity supporters included amfAR Ambassadors Milla Jovovich and Michelle Yeoh, Miley Cyrus, Dita Von Teese, Rihanna, Justin Timberlake, Tom Ford, Gwyneth Paltrow, Chiara Ferragni, Ryan Murphy, Lisa Kudrow, Rose McGowan, Jay Ellis, Eddie Redmayne, Lea Michele, Michelle Rodriguez, Rosario Dawson, Whoopi Goldberg, Chris Rock, amfAR Trustee Harry Belafonte, Naomi Campbell, Iman, Heidi Klum, Brooke Shields, Coco Rocha, Kate Moss, Cher, Kylie Minogie, Riccardo Tisci, Adrien Brody, Eva Longoria, Harvey Keitel, Harvey Weinstein, Leonardo DiCaprio, Robin Thicke, Rita Ora, Andrea Bocelli, Dean and Dan Caten, Chris Tucker, Mario Testino, Carine Roitfeld, Aishwarya Rai Bachchan, Laverne Cox, Anderson Cooper, Sandra Bernhard, Andy Cohen and Mr. Brainwash.
Program Service Accomplishments (4)Line 4d: THE GMT INITIATIVE: Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing funding for prevention and treatment services; and worked to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. In January 2015, amfAR supported a study at Instituto Pesquisa Clinica Evandro Chagas (IPEC) in Rio de Janeiro, Brazil, one of 16 clinical sites participating in the Opposites Attract Study, an ongoing international study that explores the effectiveness of "treatment as prevention" in gay male serodiscordant relationships (one sexual partner is living with HIV and the other is not). The study is led by Dr. Beatriz Grinsztejn, director of the STD/AIDS Clinical Research Laboratory at IPEC, who is monitoring as many as 70 gay male serodiscordant couples in Brazil and examining HIV treatment, viral loads, and HIV transmission to find out if HIV incidence is associated with whether the HIV-positive partner is on antiretroviral therapy. Implementation Science Awards In FY2015, the focus of amfAR's grant making through the GMT Initiative evolved from the distribution of small grants to community-based organizations to the support of larger implementation science projects aimed at identifying barriers to HIV testing, treatment and care, and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR awarded $2.6 million over three years to support three such studies. Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers will assess the effectiveness of HIV self-testing done in the privacy of one's home, point-of-care CD4 testing, and the use of "peer navigators" familiar with the local health system to help those newly diagnosed gain access to HIV treatment and care. In Lima, Peru, Dr. Javier Lama of Asociacin Civil Impacta Salud y Educacin and his team aim to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care. Working in collaboration with the Boston-based Fenway Institute and two community GMT organizations, IMPACTA and EPICENTRO, Dr. Lama and his team will integrate routine cross-sex hormone therapy into HIV and sexually transmitted infection prevention, testing and treatment services, and will implement health services and peer case management for 200 transgender women. And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre aim to show how innovative technologies such as GMT-targeted websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs. Working in collaboration with Adam's Love, a web-based health platform for GMT individuals, and two community-based organizations (Service Workers in Group/SWING and The Rainbow Sky Association of Thailand), the team will compare the effectiveness of online services and support interventions with traditional clinic-based HIV services, and a hybrid model that combines elements of both strategies. "In Action" Awards In 2015 amfAR supported five community-based organizations in Africa and Latin America in conducting formalized evaluations of their efforts to improve HIV treatment and care among GMT individuals as part of the GMT Initiative's Evidence in Action Program, which documents and evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action program and the Elton John AIDS Foundation. amfAR also supported four young researchers from Belize, China, Pakistan, and South Africa undergoing five months of graduate-level public health study at the Center for LGBT Health Research of the Graduate School of Public Health at the University of Pittsburgh as part of the amfAR HIV Scholars Program. The program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many GMT from seeking HIV testing and services. The 2015 amfAR HIV Scholars included Sheryar Kazi with the Naz Male Health Alliance, Pakistan; Liesl Theron, a consultant supported by Gender DynamiX, South Africa; Erika Castellanos from the Collaborative Network of Persons Living with HIV (C-NET+), Belize; and Weibin Cheng from the Chinese Center for Disease Control and Prevention and GZTZ.org. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations about the spread of HIV among GMT individuals and to advocate for effective strategies to address it, amfAR publishes a range of reports on HIV and GMT. In FY2015, the Foundation published Lessons From the Front Lines: Trans Health and Rights. The report, produced in collaboration with Global Action for Trans Equality (GATE), profiled 10 dynamic community organizations with strong transgender leadership in nine diverse countries-Bolivia, China, the Dominican Republic, Ecuador, El Salvador, Georgia, Peru, South Africa, and Ukraine-that are working hard to change the status quo in transgender health and rights. With support from the Arcus Foundation, the report examined data on access to health services and legal protections for transgender individuals in different settings and detailed how societal stigma and institutionalized discrimination come together to create nearly insurmountable challenges for these populations and the organizations that serve them. More importantly, however, the report described how these grassroots groups have confronted, responded to, and in some cases solved, many of the myriad challenges they face. The GMT Initiative also created a series of fact sheets in English, French, and Spanish on emerging HIV prevention technologies that explain each technology and serve as a tool to help GMT advocate for the interventions' increased availability worldwide.
Program Service Accomplishments (5)Line 4d: public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the U.S. National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill Briefings In March 2015, amfAR held a Congressional briefing in Washington, D.C., to illuminate the work that remains to be done to achieve an AIDS-free generation among women and girls in the U.S. and globally. The Capitol Hill briefing drew leaders from government, academia, and the nonprofit sector, including House Democratic Leader Nancy Pelosi, Jeannette Kagame, First Lady of Rwanda and cofounder of the Organization of African First Ladies Against HIV/AIDS, and Dr. Deborah Birx, U.S. Global AIDS Coordinator. The program also addressed medical research aimed at improving HIV prevention for women. Dr. Sharon Hillier of the University of Pittsburgh School of Medicine shared exciting progress on female-controlled HIV prevention methods, including vaginal rings containing antiretroviral (ARV) medicines, which have been shown to reduce infection rates in women 25 years of age and older. Other attendees included Reps. Nita M. Lowey and Barbara Lee, Douglas Brooks, director of the White House Office of National AIDS Policy, and Maria Cuomo Cole, chairman of HELP USA, which provides housing and other services to the homeless. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than 1.2 million people are living with the virus. In July 2015, amfAR issued a report titled Bolstering State Efforts to Implement the National HIV/AIDS Strategy: Key Indicators and Recommendations for Policymakers and Community Stakeholders. The report outlined recommendations for how states across the U.S. can improve their HIV prevention and care responses. It was released to coincide with the White House's 2015 update to the Strategy. In FY2015, the Foundation also produced issue briefs, fact sheets, special reports, and infographics on multiple critical issues, including addressing HIV among women, better responding to HIV among black gay men in the U.S., advocating harm reduction interventions to prevent the spread of HIV among PWID, and making the case for better access to hepatitis C treatment. Key Populations In February 2015, amfAR published an issue brief showing that efforts to address the HIV epidemic among black gay men have been consistently inadequate and that immediate steps must be taken to reduce new HIV infections among this underserved population. The report, titled HIV and the Black Community: Do #Black (GAY) Lives Matter? described the underlying factors contributing to elevated infection rates among black men and provided a list of steps that can be taken to mitigate this stark and persistent racial disparity. In conjunction with its Capitol Hill briefing on women and HIV in March, amfAR released a pair of issue briefs on women and HIV/AIDS in the United States and around the world. The briefs outlined policy action steps to achieve an AIDS-free generation and help more women living with the disease in the U.S. to survive and thrive. Harm Reduction/Syringe Services Programs As one of the earliest supporters of comprehensive harm reduction programs for people who inject drugs (PWID), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving HIV prevention programs. In April 2015, amfAR issued a brief titled Preventing HIV and Hepatitis C Among People Who Inject Drugs: Public Funding for Syringe Services Programs Makes the Difference. In it, amfAR underscored the importance of syringe service programs (SSPs) as a highly effective tool in the fight against the spread of HIV and hepatitis C. CEO Kevin Robert Frost also authored an op-ed on the issue for CNN.com. Another issue brief published in May and titled A Clear Case for Supporting Syringe Services Programs: New Study Shows Relationship Between Public Funding and Lower HIV Incidence, was based on a study that found a relationship between public funding of syringe services programs, reducing HIV incidence (the number of new infections in a given year), and maintaining already low HIV incidence among PWID. In its Harm Reduction and Global HIV Epidemic report, released in September 2015, amfAR assessed the state of harm reduction worldwide by focusing on the steps that five sample countries-Kenya, Kyrgyzstan, Nigeria, Ukraine, and Vietnam-have, or have not, taken to address the epidemic among PWID. Treatment Access In Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future, an issue brief published in May 2015, amfAR strongly opposed the proposed terms of the Trans-Pacific Partnership, warning that expanding existing intellectual property protections could result in a decline in generic competition and an increase in drug costs, while setting an unacceptable precedent for future free trade agreements. Two agreements being negotiated threaten the future availability of affordable generic medicines for diseases such as HIV/AIDS, cancer, tuberculosis, and hepatitis C, and could undermine the global health response in developing countries. In a February 2015 policy brief titled Hepatitis C and Drug Pricing: The Need for Better Balance, amfAR called for structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge extortionate prices for their products, however effective they may be. New pharmaceutical breakthroughs have made curing hepatitis C infection easier and more effective, but they have been priced at aggressively high rates that bear no relation to the cost of research and development. Global Health In FY 2015, amfAR launched its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFAR's planned funding of HIV/AIDS activities from 2007 to 2014. PEPFAR (the U.S. President's Emergency Plan for AIDS Relief), established in 2003, is the largest international program responding to the global HIV/AIDS epidemic and the largest commitment one nation has ever made to combat a disease internationally. The database enables users to analyze planned funding data extracted from PEPFAR's publicly released Country and Regional Operational Plan (COP/ROP) documents. It's designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders to access and understand PEPFAR's programs and priorities at a deeper level than is currently possible using other platforms.
Policiesform 990, part vi, section b Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS.
DisclosureForm 990, Part VI, Section C LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion.
Functional ExpensesPart IX, Lines 1 & 3 The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F.
Other Changes in Net AssetsFORM 990, SECTION XI, LINE 5 CHANGE IN VALUE OF THIRD PARTY TRUST............$2,556 ------- TOTAL LINE 9 $2,556

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.